Floatz logo

Bms-907351

Recurrent Thyroid Gland Carcinoma

National Cancer Institute (NCI)Phase 1Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

36 Active assets in the Recurrent Thyroid Gland Carcinoma cohort.

Asset / SponsorPhaseRating
Palbociclib
University Medical Center Groningen
Phase 4BB
LENVATINIB
University Medical Center Groningen
Phase 4BB
Olaparib
University Medical Center Groningen
Phase 4BB
gw786034
University Medical Center Groningen
Phase 4B
Cetuximab
Institut de Recherches Internationales Servier
Phase 1/2CCC

View all 39 →

Same molecule, other indications

Bms-907351 is also rated in:

renal carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
castration-resistant prostate carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →